Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein Inhibition
Authors:
Open Access
- 27 March 2025
- journal article
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 14 (5) , 368-381
Abstract
Soticlestat (TAK‐935) is a cholesterol 24‐hydroxylase inhibitor. A physiologically‐based pharmacokinetic model has been developed to predict potential soticlestat drug–drug interactions (DDIs) using the Simcyp v20 Population‐based Simulator and verified with data from single‐/multiple‐rising‐dose and clinical DDI studies. Simulated area under the plasma concentration–time curve from 0 to infinity (AUC0‐inf) and maximal drug concentration (Cmax) based on the model were generally within 2‐fold of observed values for all soticlestat doses. Model‐simulated versus observed AUC0‐inf and Cmax geometric mean ratios (GMRs) for soticlestat with/without itraconazole (potent cytochrome P450 [CYP] 3A inhibitor), and mefenamic acid (potent UDP glucuronosyltransferase [UGT] 1A9 inhibitor) were ≤1.10‐fold. As soticlestat is primarily metabolized by UGT enzymes and Simulator v20 incorporates rifampin's induction of CYP3A only, the model underpredicted soticlestat's DDI with rifampin. However, with user‐defined rifampin UGT induction, the predicted AUC0‐inf GMR was within 1.5‐fold of the observed value, meeting the 2‐fold acceptance criteria. Hence, the model was appropriate for evaluating DDIs with CYP3A inhibitors and inducers not evaluated in clinical DDI studies; all predicted DDIs were low/not clinically relevant (<50% impact on exposure). Furthermore, no clinically significant DDIs were predicted following coadministration of soticlestat with sensitive CYP2C8, CYP2C9, CYP2C19, CYP3A4, and P‐glycoprotein substrates.Keywords
This publication has 52 references indexed in Scilit:
- Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose RegimensThe Journal of Clinical Pharmacology, 2021
- Proposal of a Safe and Effective Study Design for CYP3A‐Mediated Drug‐Drug InteractionsThe Journal of Clinical Pharmacology, 2020
- Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic ModelCPT: Pharmacometrics & Systems Pharmacology, 2019
- Ketoconazole and Liver Injury: A Five‐Year UpdateClinical Pharmacology in Drug Development, 2019
- Rifampin modulation of xeno‐ and endobiotic conjugating enzymemRNAexpression and associated microRNAs in human hepatocytesPharmacology Research & Perspectives, 2018
- No Increased Risk of Ketoconazole Toxicity in Drug–Drug Interaction StudiesThe Journal of Clinical Pharmacology, 2016
- Ketoconazole‐Associated Liver Injury in Drug‐Drug Interaction Studies in Healthy VolunteersThe Journal of Clinical Pharmacology, 2016
- A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein‐bound drugs and the impact of errors in plasma protein bindingBiopharmaceutics & Drug Disposition, 2015
- Evidence‐based choice of ritonavir as index CYP3A inhibitor in drug‐drug interaction studiesThe Journal of Clinical Pharmacology, 2015
- Best practices for the use of itraconazole as a replacement for ketoconazole in drug–drug interaction studiesThe Journal of Clinical Pharmacology, 2015